Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: A prospective multicenter study

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 552-558

  Buhk, Jan Hendrik ^a,b   Jung, Sabine ^a   Psychogios, Marios Nikos ^a   Göricke, Sophia ^c   Hartz, Sabine ^d   Schulz Heise, Susanne ^e   Klingebiel, Randolf ^f   Forsting, Michael ^c   Brückmann, Hartmut ^d   Dörfler, Arnd ^e   Jordan, Martina ^g   Buchfelder, Michael ^e   Knauth, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g ClinSupport GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; GROWTH HORMONE SECRETING ADENOMA; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 76149110780     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1239     Document Type: Article

References (29)

1. Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 151:1573-1578
2. Jaffe CA, Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
3. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 80:2768-2775
4. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
5. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355: 2558-2573
6. Vallette S, Serri O 2008 Octreotide LAR for the treatment of acromegaly. Expert Opin Drug Metab Toxicol 4:783-793
7. Chanson P 2008 Emerging drugs for acromegaly. Expert Opin Emerg Drugs 13:273-293
8. Chen WY, Wight DC, Wagner TE, Kopchick JJ 1990 Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 87:5061-5065
9. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA 1992 Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-1680
10. Trainer PJ, DrakeWM,Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
11. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
12. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ 2001 Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 145:451-456
13. Hodish I, BarkanA2008 Long-term effects of pegvisomant in patients with acromegaly. Nat Rev Endocrinol 4:324-332
14. Drake WM, Berney DM, Kovacs K, Monson JP 2005 Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol 153:203-205
15. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
16. Frohman LA, Bonert V 2007 Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 10: 283-289
17. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82
18. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF 2008 Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159:517-523
19. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B 2007 Experience from the German pegvisomant observational study. Horm Res 68(Suppl 5):70-73
20. Trainer PJ 2007 ACROSTUDY: an overview. Horm Res 68(Suppl 5): 68-69
21. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
22. Besser GM, Burman P, Daly AF 2005 Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 153: 187-193
23. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW 2001 Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86:478-481
24. Bevan JS 2005 Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
25. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G 1997 Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277-284
26. Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR 1999 Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 22:409-418
27. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
28. Benesch H, Felber SR, Finkenstedt G, Kremser C, Stockhammer G, Aichner FT 1995MRvolumetry for monitoring intramuscular bromocriptine treatment in macroprolactinomas. J Comput Assist Tomogr 19:866-870
29. McGrath GA, Goncalves RJ, Udupa JK, Grossman RI, Pavlou SN, Molitch ME, Rivier J, Vale WW, Snyder PJ 1993 New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 76:1363-1368